Charles Sternberg, Assistant Editor04.19.21
Evotec SE has entered into a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialization of Evotec's oncology project EVT801.
EVT801 is a pre-clinical-stage, orally available, small molecule inhibitor of the lymphatic growth factor receptor VEGFR3, originally developed within Evotec's partnership with Sanofi. The high selectivity of EVT801 for VEGFR3 over other VEGF receptors differentiates the compound from other small-molecule multi-kinase inhibitors that target multiple VEGF receptors, which are associated with significant toxicity. EVT801 provides the potential to specifically antagonize VEGFR3 to combine high efficacy both against the primary tumor and lymphatic-borne metastases with a highly favorable toxicology profile.
Kazia seeks to clinically evaluate EVT801 both as a single agent and in combination with immunotherapy in a set of specific oncology indications. Evotec will manage the Phase I trial under the full sponsorship of Kazia. Kazia will be responsible for any subsequent clinical evaluation and commercialization of EVT801.
Evotec receives a small upfront payment as well as further payments for continued support progressing EVT801 into the clinic and beyond, e.g. for biomarker development and CMC. Additionally, Evotec is eligible to receive clinical and commercial milestones of more than €300 million ($360.8 million) as well as tiered high single-digit royalties on the net sales of EVT801, which will be shared with Sanofi, Evotec's partner for the discovery and early development of EVT801.
Comments from Leadership
Dr Cord Dohrmann, chief scientific officer of Evotec, commented, "We look forward to working with Kazia, to make EVT801 available to patients globally, thus providing a new treatment option for their severe unmet medical needs."
Dr James Garner, chief executive officer of Kazia, added, "We are delighted to add this tremendously exciting new compound to the Kazia pipeline. Evotec have done first-class work in the early development of EVT801, and the preclinical data package is exceptionally strong. Our intention is to fast track a phase I clinical trial of the drug, which we expect to commence in CY2021."
EVT801 is a pre-clinical-stage, orally available, small molecule inhibitor of the lymphatic growth factor receptor VEGFR3, originally developed within Evotec's partnership with Sanofi. The high selectivity of EVT801 for VEGFR3 over other VEGF receptors differentiates the compound from other small-molecule multi-kinase inhibitors that target multiple VEGF receptors, which are associated with significant toxicity. EVT801 provides the potential to specifically antagonize VEGFR3 to combine high efficacy both against the primary tumor and lymphatic-borne metastases with a highly favorable toxicology profile.
Kazia seeks to clinically evaluate EVT801 both as a single agent and in combination with immunotherapy in a set of specific oncology indications. Evotec will manage the Phase I trial under the full sponsorship of Kazia. Kazia will be responsible for any subsequent clinical evaluation and commercialization of EVT801.
Evotec receives a small upfront payment as well as further payments for continued support progressing EVT801 into the clinic and beyond, e.g. for biomarker development and CMC. Additionally, Evotec is eligible to receive clinical and commercial milestones of more than €300 million ($360.8 million) as well as tiered high single-digit royalties on the net sales of EVT801, which will be shared with Sanofi, Evotec's partner for the discovery and early development of EVT801.
Comments from Leadership
Dr Cord Dohrmann, chief scientific officer of Evotec, commented, "We look forward to working with Kazia, to make EVT801 available to patients globally, thus providing a new treatment option for their severe unmet medical needs."
Dr James Garner, chief executive officer of Kazia, added, "We are delighted to add this tremendously exciting new compound to the Kazia pipeline. Evotec have done first-class work in the early development of EVT801, and the preclinical data package is exceptionally strong. Our intention is to fast track a phase I clinical trial of the drug, which we expect to commence in CY2021."
